Printer Friendly

T CELL SCIENCES REPORTS NEW DATA ON sCR1

 T CELL SCIENCES REPORTS NEW DATA ON sCR1
 CAMBRIDGE, Mass., March 3 /PRNewswire/ -- T Cell Sciences, Inc.


(NASDAQ: TCEL), today reported that a protein being developed as the company's first therapeutic product significantly reduced tissue injury in several animal models of inflammation.
 The protein, sCR1, limited tissue injury by reducing neutrophil content in the area of inflammation in these animal models by at least 68 percent. These results support possible use of sCR1 in human disease conditions in which similar inflammatory events occur, such as adult respiratory distress syndrome (ARDS), complications of cardiopulmonary bypass, and renal disease.
 The results of this study are reported in a paper appearing in the current issue of the Journal of Immunology. Previously, sCR1 has been the subject of several published studies showing the protein's ability to limit complement-mediated inflammatory tissue damage that occurs in heart reperfusion (the re-establishment of blood flow to the heart following a period of ischemia), and allograft (same species) and xenograft (cross-species) organ transplantation. T Cell Sciences continues additional animal studies to evaluate the protective effects of sCR1 in several inflammatory conditions.
 "At this time physicians do not have any practical way to treat complement-mediated inflammatory tissue damage which occurs in many medical conditions," commented Alfred Rudolph, M.D., senior vice president of T Cell Sciences. "Based on the results seen in animals, we are very encouraged by the development of this product to date." CR1 is a human regulatory protein of the complement system that functions to depress complement-mediated inflammatory signals. sCR1 is a recombinantly produced modified version of the naturally occurring protein which can be administered to reduce tissue damage.
 The published study, "Protective Effects of Soluble CR1 in Complement and Neutrophil-mediated Tissue Injury," was authored by scientists Grace Yeh and Alfred Rudolph of T Cell Sciences, and Michael Mulligan and Peter Ward of the University of Michigan Medical School.
 Located in Cambridge, Mass., T Cell Sciences, Inc., is utilizing proprietary T cell receptor and soluble receptor technology to develop pharmaceutical products to treat heart disease, inflammatory diseases, autoimmune diseases and cancer. T Cell Diagnostics, Inc., a subsidiary of T Cell Sciences, develops, manufactures and markets products for monitoring immune system disorders.
 -0- 3/3/92 R
 /CONTACT: Alfred R. Rudolph, M.D., senior vice president, or Susan Primrose of T Cell Sciences, 617-621-1400/
 (TCEL) CO: T Cell Sciences, Inc. ST: Massachusetts IN: MTC SU:


GK -- NY027R -- 4379 03/03/92 09:59 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 3, 1992
Words:406
Previous Article:HEMODYNAMICS ANNOUNCES OFFERING BY PROTECTIVE APPAREL CORPORATION
Next Article:SMOKING BY PARENTS TAKES AN EMOTIONAL TOLL ON CHILDREN, A NEW HARRIS POLL SUGGESTS DAY
Topics:


Related Articles
T CELL SCIENCES AND SMITHKLINE BEECHAM ANNOUNCE IND FILING FOR SCR1 FOR THE TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
T CELL SCIENCES AND SMITHKLINE BEECHAM AGREE TO MODIFY SCR1 DEVELOPMENT AND LICENSE AGREEMENT
sCR1 CLINICAL DEVELOPMENT TRANSFERRED TO T CELL SCIENCES
T CELL SCIENCES REPORTS FIRST QUARTER RESULTS
T CELL SCIENCES ANNOUNCES NEW COMPLEMENT INHIBITOR AGREEMENT WITH SMITHKLINE BEECHAM, p.l.c.
T CELL SCIENCES REPORTS THIRD QUARTER 1994 FINANCIAL RESULTS
TCELL SCIENCES PRESENTS INITIAL DATA ON NOVEL COMPLEMENT/CELL ADHESION INHIBITOR FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
T CELL SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR sCR1 IN ARDS
T CELL SCIENCES AND SMITHKLINE BEECHAM TERMINATE COMPLEMENT INHIBITOR AGREEMENT
T CELL SCIENCES AND COLLABORATORS DEMONSTRATE ABILITY TO BLOCK HYPERACUTE XENOGRAFT ORGAN REJECTION USING SCR1

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters